NDPS Controlled Substance Alert: New Registration Deadlines Hit in July 2026

Three NDPS Developments Pharma Companies Cannot Afford to Miss This Quarter

A gazette notification quietly issued in March 2026 has created a hard compliance deadline that lands within days — on July 10, 2026. Simultaneously, a landmark decision at the 68th Drugs Consultative Committee (DCC) meeting is reshaping how the entire NDPS-regulated pharmaceutical supply chain will be monitored going forward. And the newly released NCB Vision Document 2026–2029 places explicit voluntary compliance obligations on the chemical and pharmaceutical industries. For companies operating anywhere in the narcotic or psychotropic substance space, the next twelve weeks are critical.

Development 1: New Controlled Substance Notified — Deadlines Start July 10, 2026

On March 11, 2026, the Department of Revenue, Ministry of Finance, issued Notification S.O. 1259(E), bringing 2-Bromo-4-Methylpropiophenone (CAS No. 1451-82-7) under regulatory control as a controlled substance under the Narcotic Drugs and Psychotropic Substances (Regulation of Controlled Substances) Order, 2013. The reason: its documented and increasing use as a precursor in the illicit manufacture of mephedrone (4-methylmethcathinone), a Schedule I psychotropic substance.

The Narcotics Control Bureau (NCB) subsequently issued a public notice on June 16, 2026 operationalising the notification for industry. This chemical is used in legitimate pharmaceutical synthesis, meaning manufacturers, API producers, distributors, importers, exporters, and traders who handle it — including through online or electronic platforms — are now squarely within NDPS regulatory oversight.

What the Notification Requires — and When

• By July 10, 2026: All entities holding stocks of 2-Bromo-4-Methylpropiophenone as of June 30, 2026 must declare their inventory to the respective Zonal Director, NCB, in Form X. This is a non-negotiable stock-declaration requirement — failure to comply is a violation of the NDPS (RCS) Order, 2013.
• By August 7, 2026: All persons and entities engaged in the manufacture, distribution, sale, purchase, possession, storage, consumption, import, or export of this chemical must submit Form B registration applications to the concerned NCB Zonal Unit to obtain a Form A registration number from the jurisdictional Zonal Director, NCB — well in advance of the statutory 180-day issuance window running from March 11.
• From September 7, 2026: Any entity dealing with 2-Bromo-4-Methylpropiophenone in contravention of NDPS Act provisions after this date will face penal action under Section 25A of the NDPS Act, 1985 — which carries serious criminal liability.

With the July 10 deadline now days away, any company that has not yet identified its 2-Bromo-4-Methylpropiophenone inventory must act immediately. India has now notified 27 precursor chemicals as controlled substances in total — this addition signals continued expansion of that list.

Development 2: Real-Time NDPS Digital Tracking Portal — Approved, Now in Development

At the 68th Drugs Consultative Committee (DCC) Meeting held on March 20, 2026 (conducted in hybrid mode), the committee approved a proposal for a centralized, real-time, end-to-end digital tracking portal for all pharmaceutical products regulated under the NDPS Act. The committee was specifically apprised of the urgent need to create a mechanism covering the manufacture, import/export, sale, distribution, and stock of NDPS-regulated pharma products — and deliberated on the portal’s functional architecture, the respective roles of CDSCO and State Drug Regulatory Authorities, and the legal framework underpinning it.

This approval directly responds to a surge in pharmaceutical drug diversion that has been recorded nationwide throughout 2026. Multi-state police operations in June 2026 uncovered thousands of units of Diazepam injections, Tramadol capsules, Pregabalin, and codeine-based cough syrups diverted from legitimate pharmaceutical supply chains. The DCC’s portal initiative reflects regulatory acknowledgement that the current paper-based and manual tracking systems are inadequate.

What This Means for Pharma Companies Right Now

The portal is approved but not yet live. However, manufacturers and distributors of NDPS-regulated products should treat this as a clear signal:

• Audit your internal traceability systems now. When the portal goes live, you will be expected to upload or integrate real-time data on manufacture, dispatch, and distribution of NDPS products. Companies with manual records will face a steep onboarding challenge.
• Strengthen distributor documentation. Each hand-off point in the supply chain — from manufacturer to C&F agent, stockist, and retailer — must be fully documented. Enforcement agencies are already targeting gaps at exactly these points.
• Review your Schedule H and H1 formulations compliance. The DCC’s portal specifically covers Schedule H and H1 formulations in its scope — companies manufacturing these must ensure that their dispensing, prescription, and sale records are complete and auditable.

Development 3: NCB Vision Document 2026–2029 — Voluntary Compliance as a Hard Expectation

The NCB Vision Document on Drug Control (2026–2029), released at the 10th Apex-Level NCORD meeting chaired by Union Home Minister Amit Shah, sets out a time-bound national strategy that has direct implications for the pharmaceutical and chemical industries.

The document calls for the chemical and pharmaceutical industries to adopt voluntary compliance and flag suspicious transactions proactively. It also mandates that financial investigations be conducted in all major drug cases — with greater use of the PITNDPS Act (Prevention of Illicit Traffic in Narcotic Drugs and Psychotropic Substances Act, 1988) to attach illicit assets. The strategic focus on synthetic drugs, particularly methamphetamine and mephedrone, and tighter precursor controls signals further controlled substance notifications in coming months.

Technology-driven enforcement — including AI-enabled profiling and advanced container scanning — is a core pillar of the Vision Document, meaning that the regulatory and enforcement environment for NDPS-regulated pharma will become significantly more sophisticated over the next three years.

The Judicial Landscape: Dual Applicability Still Firmly Established

A live risk for pharma companies remains the courts’ settled position that regulatory classification under the Drugs and Cosmetics Act does not insulate a company or individual from NDPS Act exposure. Courts have consistently emphasised that therapeutic recognition of a substance is distinct from the therapeutic legality of conduct — and that misuse cannot be legitimised merely because the product carries a valid drug licence. The burden of establishing entitlement to any NDPS exemption (for example, for codeine preparations under Notification S.O. 826(E)) lies squarely on the accused, and failure to meet even one cumulative condition — concentration limits, compounding with other therapeutic ingredients, establishment in therapeutic practice — revives full NDPS prohibition under Section 8.

This judicial clarity means that robust internal compliance — not just regulatory licensing — is the only credible defence in enforcement situations.

Priority Action Checklist for Pharma Companies (June–September 2026)

1. Immediately: Identify all stocks of 2-Bromo-4-Methylpropiophenone held as of June 30, 2026, and prepare Form X declarations for submission to the Zonal NCB Director by July 10, 2026.
2. By August 7, 2026: Submit Form B registration applications to the relevant NCB Zonal Unit to secure your Form A registration number before the September 7 enforcement date.
3. Ongoing: File monthly returns for narcotic drugs and psychotropic substances by the 7th of each month — non-compliance jeopardises future export authorisations and CBN quota allocations.
4. Supply chain audit: Review distributor agreements, dispatch documentation, and stock reconciliation records for all Schedule H1 and NDPS-regulated products in your portfolio.
5. Digital readiness: Begin mapping your NDPS product data flows in preparation for the forthcoming centralized DCC tracking portal; companies with ERP or digital inventory management systems should assess API integration options now.
6. Suspicious transaction reporting: Under the Vision Document 2026–2029 framework, build internal escalation protocols for identifying and reporting unusual ordering patterns for controlled substances and their precursors.
7. Review your Schedule list: With 27 controlled substances now notified and more expected, assign a responsible compliance officer to track S.O. notifications from the Department of Revenue on a rolling basis.

ACPL’s regulatory experts can help you navigate narcotics and NDPS Act compliance for your pharmaceutical business. Contact us at info@acplgroupindia.co.in or call +91-9266665201 for a consultation.